Journal
BIOLOGICAL PSYCHIATRY
Volume 62, Issue 8, Pages 835-838Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2006.12.020
Keywords
cognitive-behavioral therapy; D-cycloserine; obsessive-compulsive disorder; treatment
Categories
Ask authors/readers for more resources
Background: D-cycloserine (DCS), a glutamatergic partial N-methyl-D-aspartate (NMDA) agonist, can facilitate extinction learning related to cued fear in animals and humans. We predicted that DCS would accelerate obsession-related distress reduction in patients with obsessive-compulsive disorder (OCD) undergoing extinction-based exposure therapy. Methods: We administered DCS (1125 mg) or placebo in a double-blind fashion to individuals with OCD approximately 2 hours before each exposure session. Results: D-cycloserine decreased both the number of exposure sessions required to achieve clinical milestones and the rate of therapy dropout. After four exposure sessions, patients in the DCS group reported significantly greater decreases in obsession-related distress compared with the placebo group; however, after additional sessions, the placebo group tended to catch up. Conclusions: D-cycloserine augmentation has the potential to increase the efficiency, palatability, and overall effectiveness of standard exposure therapy for OCD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available